Novavax's Vaccine Data Keeps Getting Better
In this video from Motley Fool Live, recorded on March 15, Fool.com contributors Brian Orelli and Keith Speights discuss the final analysis of data from clinical trials testing Novavax's (NASDAQ: NVAX) coronavirus vaccine. The data compare well to the mRNA-based vaccines when just looking at the original strain of the virus. And there's some evidence that Novavax's vaccine is also protecting against the U.K. variant, and to a lesser extent against the South African variant.
Source Fool.com
